Sigma Planning Corp Grows Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

Sigma Planning Corp grew its holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) by 68.3% during the third quarter, HoldingsChannel.com reports. The firm owned 212,410 shares of the company’s stock after acquiring an additional 86,185 shares during the quarter. Sigma Planning Corp’s holdings in Aileron Therapeutics were worth $752,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. University of Texas Texas AM Investment Management Co. purchased a new stake in Aileron Therapeutics in the second quarter worth $4,925,000. Nantahala Capital Management LLC increased its stake in Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares during the period. Warberg Asset Management LLC purchased a new stake in Aileron Therapeutics in the second quarter worth $86,000. Texas Capital Bank Wealth Management Services Inc increased its stake in Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock worth $174,000 after purchasing an additional 10,398 shares during the period. Finally, KG&L Capital Management LLC purchased a new stake in Aileron Therapeutics in the third quarter worth $46,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Trading Down 6.8 %

Shares of Aileron Therapeutics stock opened at $3.57 on Thursday. The firm has a market cap of $77.36 million, a P/E ratio of -1.10 and a beta of 2.35. Aileron Therapeutics, Inc. has a 12 month low of $1.52 and a 12 month high of $7.42. The stock’s fifty day moving average price is $3.47 and its 200-day moving average price is $3.16.

Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.20). Analysts forecast that Aileron Therapeutics, Inc. will post -1.41 earnings per share for the current year.

Aileron Therapeutics Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).